{
  "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
  "docSlug": "c241ac9edd2443452257949ce0a73d65",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 61,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a longitudinal timeline comparison to highlight the superior safety and efficacy profile of NXC-201.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/16",
  "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
  "deckJsonHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920.json",
  "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.85,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Comparative longitudinal charts of CAR-T cell expansion and sBCMA levels",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fdef0ec-55c1-4bf3-8983-d10f5f38dfaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.1,
        "x": 0.88,
        "y": 0.15
      },
      "kind": "list",
      "text": "1. CRS duration comparison; 2. Neurotoxicity duration comparison; 3. sBCMA reduction speed; 4. CAR-T cell persistence comparison",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4af7c0b3-5b28-4b39-a295-da713172d7de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: FDA labels; company presentations; EMA assessment report; et al. (full citation in footer)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "781f03b6-5438-45c1-aa70-4a9360937474",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "N-GENIUS Technology Platform – NXC-201 rapidly eliminates relapsed/refractory multiple myeloma tumors, driving dramatically improved tolerability (1/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c3c677f-c93c-4588-8fd7-2e9c05b4cacf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "d46c6cd9-90eb-48eb-b4cc-60d0e157a777",
      "evidence": "Direct visual comparison of clinical trial data across three different therapies.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 10,
      "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}